Human Reproduction, Vol. 15, No. 6, 1421,
June 2000
© 2000 European Society of Human Reproduction and Embryology
Letters to the Editor |
Pediatric Neurology Unit, Assaf Harofeh Medical Center, Zerifin 70300, Israel
Dear Sir,
Dr Platteau et al. commented on two issues which should be separately regarded. The first issue is congenital malformation and the second one is neurodevelopmental abnormalities.
Considering the first issue, congenital malformation, the incidence of one case out of six does not mean too much and still stands in the accepted incidence as was mentioned by Dr Platteau et al.
Regarding the second issue, namely neurodevelopmental abnormalities, so far nothing has been documented in the literature because no late follow up of inadvertent pregnancies under GnRH agonist treatment have been far reported. Since our late follow up of such infants is the first, we were quite surprised to encounter neurodevelopmental abnormalities in four out of six cases.
The 37th gestational week is considered as term pregnancy. Regarding the data of the infants, we do apologize for our error in Table II (Lahat et al., 1999
); Case no. 1—gestational age should be 37 weeks and not 35 weeks as written.
We completely agree with the comment that we have to be careful not to create any unnecessary fear and confusion, therefore we concluded our manuscript by writing that `additional long term follow-up studies of such children are urgently needed before drawing any conclusions'.
Notes
1 To whom correspondence should be addressed 
References
Lahat, E., Raziel, A., Friedler, S. et al. (1999) Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist in early pregnancy. Hum. Reprod., 14, 2656–2660.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||